In order to significantly reduce the side effects of current therapeutic approaches and to increase quality of life and life expectancy, we propose to develop an integrated simultaneous imaging/therapeutic (“theranostic”) platform that will allow diagnostic imaging, targeted image guided surgical, photodynamic and radiopeptide therapy to selectively resect or destroy diseased beta cells. This technology is based on European cutting-edge molecular imaging technology for in vivo imaging of beta cells developed in previous EU FP7 projects currently in the phase of successful clinical evaluation.

This platform will enable delivery of individual patient-tailored therapy with high precision, increasing cure rate while significantly reducing or even avoiding side effects. The platform will allow diagnosis and monitoring of disease, it will support and guide therapeutic intervention and it will help to predict the outcome of intervention and the individual prognosis.

The theranostic platform will not only allow to optimize treatment of newborns and infants suffering from congenital hyperinsulinism (CHI) but also allow improved treatment of adult hyperinsulinemic hypoglycemia (AHH) caused by insulin-producing tumours (insulinomas) or adult beta cell hyperplasia (currently named nesidioblastosis).